HM to DCGI: To ensure equitable distribution of ‘investigational therapy’ drugs nationwide

Distribution of drugs across the country included as part of "investigational therapies" in clinical management protocol for COVID-19

Injection Medicine
Picture: Pixabay

NEW DELHI: The Union Health and Family Welfare Ministry has directed the Drugs Controller General of India (DCGI) to ensure equitable distribution of drugs across the country included as part of “investigational therapies” in clinical management protocol for COVID-19.

According to a Health Ministry official, the move comes when Arunachal Pradesh, Dadra and Nagar Haveli and Daman and Diu informed the ministry of the requirement of investigational therapy drugs

“With the intervention of DCGI, smaller States and Union Territories (UTs) were provided with adequate quantities of drugs under the investigational therapy for the treatment of COVID-19 patients,” said the official.

Also read: Avra Lab gets CDSCO nod for favipiravir API

A letter written by the senior Health Ministry official to the DCGI stated, “I am directed to say that apart from availability, the geographical distribution/reach of the drugs included as part of investigational therapies in clinical management protocol for COVID-19, namely, Remdesivir and Tocilizumab, may also be monitored.”

“The Ministry may kindly be apprised as to how many States/UTs have been covered and which of the States/UTs, if any, are left as far as the availability/distribution of these drugs by the respective companies is concerned,” read the letter.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.


Please enter your comment!
Please enter your name here